Ixekizumab for the treatment of psoriasis: an update on new data since first approval

Keyphrases

• Psoriasis Treatment 100%
• First Approval 100%
• Ixekizumab 100%
• Psoriatic Arthritis 50%
• Psoriasis 25%
• Interleukin-17 (IL-17) 25%
• Plaque Psoriasis 25%
• Inflammatory Cytokines 12%
• Inflammatory Bowel Disease 12%
• Adalimumab 12%
• Invasive Candidiasis 12%
• Safety Profile 12%
• Treatment Setting 12%
• Monoclonal Antibody 12%
• Area Cover 12%
• Etanercept 12%
• Multifactorial Etiology 12%
• Moderate-to-severe Psoriasis 12%
• Phase I Study 12%
• Expert Commentary 12%
• New Indication 12%
• Cytokines/interleukins 12%
• Immune-mediated Skin Diseases 12%
• Ustekinumab 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis 100%
• Ixekizumab 100%
• Psoriatic Arthritis 37%
• Psoriasis Vulgaris 37%
• Biological Product 25%
• Interleukin 17 25%
• Cytokine 12%
• Clinical Study 12%
• Monoclonal Antibody 12%
• Skin Disease 12%
• Etanercept 12%
• Inflammatory Bowel Disease 12%
• Adalimumab 12%
• Ustekinumab 12%
• Candidiasis 12%
• Diseases 12%
• Etiology 12%
• Pathogenesis 12%